Edesa Biotech (EDSA) cleared by FDA to add sub-study to its ongoing Phase 2/Phase 3 clinical study of its investigational drug, EB05, for ARDS

Go back to Edesa Biotech (EDSA) cleared by FDA to add sub-study to its ongoing Phase 2/Phase 3 clinical study of its investigational drug, EB05, for ARDS

Edesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy

January 26, 2021 7:31 AM EST

TORONTO, ON / ACCESSWIRE / January 26, 2021 / Edesa Biotech, Inc. (NASDAQ: EDSA), a clinical-stage biopharmaceutical company, has received regulatory approval from the U.S. Food and Drug Administration (FDA) and Health Canada to add a sub-study to its ongoing Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of Acute Respiratory Distress Syndrome (ARDS) - the leading cause of death in COVID-19 patients. The sub-study will evaluate the drug as a potential rescue therapy for critically severe COVID-19 cases.

Dr. Par Nijhawan, Chief Executive Officer of Edesa, said that... More